Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Total Non-Current Liabilities: 2011-2024

Historic Total Non-Current Liabilities for Ani Pharmaceuticals (ANIP) over the last 9 years, with Dec 2024 value amounting to $835.3 million.

  • Ani Pharmaceuticals' Total Non-Current Liabilities rose 6.52% to $891.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $891.0 million, marking a year-over-year increase of 6.52%. This contributed to the annual value of $835.3 million for FY2024, which is 97.56% up from last year.
  • Per Ani Pharmaceuticals' latest filing, its Total Non-Current Liabilities stood at $835.3 million for FY2024, which was up 97.56% from $422.8 million recorded in FY2023.
  • Ani Pharmaceuticals' Total Non-Current Liabilities' 5-year high stood at $835.3 million during FY2024, with a 5-year trough of $251.0 million in FY2020.
  • For the 3-year period, Ani Pharmaceuticals' Total Non-Current Liabilities averaged around $548.2 million, with its median value being $422.8 million (2023).
  • Data for Ani Pharmaceuticals' Total Non-Current Liabilities shows a peak YoY surged of 97.56% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Ani Pharmaceuticals' Total Non-Current Liabilities stood at $251.0 million in 2020, then soared by 52.13% to $381.9 million in 2021, then rose by 1.21% to $386.5 million in 2022, then rose by 9.40% to $422.8 million in 2023, then soared by 97.56% to $835.3 million in 2024.